Cannan Caton lives with Common Variable Immune Deficiency (CVID), a rare disorder that makes it hard to fight infections. He depends on intravenous immunoglobulin (IVIG) therapy—made possible by plasma donation and the therapies Fresenius Kabi helps mak...

We urge the administration to consider the rights of all people, including those who are immunocompromised or cannot be safely vaccinated, and rescind this dangerous executive order.

The more you understand about primary immunodeficiency (PI), the better you can manage it. Learn about PI diagnoses and treatment options.

Georgetown ethicist Peter Jaworski discusses the global plasma shortage and myths surrounding plasma donation.

Grifols is voluntarily withdrawing one lot of Gamunex-C, 40G vials, and one lot of GammaKed, 20G vial.

Recent changes to the Advisory Committee on Immunization Practices (ACIP) and proposed legislative efforts--such as the “End the Vaccine Carveout Act”--are eroding public confidence in vaccines.

Researchers have launched a multi-site research study, called MIRACLE, to help answer questions about fertility and pregnancy in people with primary immunodeficiency (PI).

A strong, united voice can influence public policy issues that impact your health and access to care. Reaching out to your public officials is simple and quick with the Immune Deficiency Foundation Ac...

IDF advocates with policymakers and payers for insurance coverage of immunoglobulin (Ig) replacement therapy for those with PI, including access to specific Ig products, modes of administration, and s...

A strong, united voice can influence public policy issues that impact your health and access to care. Reaching out to your public officials is simple and quick with the Immune Deficiency Foundation Ac...

While broadly following AAFP and AAP guidelines, the foundation supports IDSA’s new recommendation that all immunocompromised adults ages 18+ receive a respiratory syncytial virus (RSV) vaccine.

Respiratory syncytial virus (RSV) can cause severe respiratory infections. Merck's Enflonsia is the third monoclonal antibody approved to prevent RSV in infants born during or entering their first RSV season.

The Immune Deficiency Foundation names Paula Henao, MD, as new medical director.

2025’s four Research Grant Program awardees will use their funding to better understand some of the rarest primary immunodeficiencies (PIs) and develop diagnostics and treatments.